{"id":"W2946957740","doi":"10.1016/j.clgc.2021.05.004","title":"Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; McMaster University; Sunnybrook Health Science Centre; University of Manitoba; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; University of Ottawa","funders":"Genentech; Ipsen; Amgen Astellas Biopharma; Astellas Pharma; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; AbbVie; Exelixis; Sanofi; Roche; Karyopharm Therapeutics; Novartis; MedImmune; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Hazard ratio; Renal cell carcinoma; Internal medicine; Kidney cancer; Systemic therapy; Cancer; Cohort study; Confidence interval; Oncology; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001979091,0.0004877123,0.00057775,0.003485266,0.001390471,0.00137854,0.001357592,0.0005608479,0.00238776],"category_scores_gemma":[0.009338692,0.0002191366,0.0008785416,0.009955505,0.00033841,0.0005891332,0.001157973,0.0007387158,0.0002575021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02679486,"about_ca_system_score_gemma":0.04659624,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9936293,"about_ca_topic_score_gemma":0.9955699,"domain_scores_codex":[0.9973291,0.0002231254,0.0001758964,0.0002082457,0.001466623,0.0005970258],"domain_scores_gemma":[0.992469,0.000485154,0.00103296,0.0001203175,0.004726809,0.001165746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001948066,0.00005269633,0.973474,0.000192628,0.0001363755,0.00004163526,0.0003114189,0.0004003647,0.000096982,0.0001579677,0.01188625,0.01305479],"study_design_scores_gemma":[0.00001444168,0.00002014692,0.9961486,0.00005968435,0.00007596858,0.0000252158,0.0003209375,0.0004531978,0.00005740428,0.0000202185,0.002793686,0.00001043233],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7993615,0.007000303,0.0002942612,0.004441966,0.0001036984,0.0002640957,0.1666888,0.00009231688,0.02175308],"genre_scores_gemma":[0.953845,0.002751515,0.0004363775,0.0006402367,0.00004800727,0.0000602558,0.04005361,0.00001847998,0.002146514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02679486,"threshold_uncertainty_score":0.1944112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05802921157147152,"score_gpt":0.3275666794121709,"score_spread":0.2695374678406994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}